Indicator selection may have hindered behaviour change efforts
Participants stated that of the three indicators, responding to the antipsychotic medication indicator by appropriately adjusting their prescribing was more of a priority than responding to the benzodiazepine indicator. Prioritisation of the “three or more specified CNS-active medications” indicator (i.e., the trial primary outcome) was rarely discussed. Participants expressed challenges with interpreting this indicator, specifically with identifying which medications were included. This precluded their ability to make sense of the data in order to influence behaviour change. This corresponded to CFIR domains “The 3 or more specified I have to admit I don’t know where it’s specified. I don’t know which drugs they’re talking about.” (LTC2, benefit, top quartile)